Cilla Savino, Rossi Romina, Donati Costanza Maria, Habberstad Ragnhild, Klepstad Pal, Dall'Agata Monia, Valenti Vanessa, Kaasa Stein, Medici Federica, Morganti Alessio Giuseppe, Maltoni Marco
Medical Physics Unit, Responsible Research Hospital, Campobasso, Italy.
Palliative Care Unit, Institute of care with a scientific character (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy.
Clin Med Insights Oncol. 2025 Mar 24;19:11795549241297054. doi: 10.1177/11795549241297054. eCollection 2025.
Bone metastases (BMs) are a common complication in patients with cancer, often leading to significant pain that adversely affects quality of life, necessitating effective pain management strategies. This study aims to evaluate the effectiveness of pain management in patients with BMs undergoing palliative radiotherapy and to identify determinants of pain management adequacy.
We conducted an observational analysis of 560 patients from the Palliative Radiotherapy and Inflammation Study (PRAIS) trial across several European centers, focusing on the Pain Management Index (PMI) for assessing pain management adequacy. Key predictors examined included Karnofsky Performance Status (KPS), treatment setting, primary tumor type, and site of BMs.
Our findings indicate that 19.0% of patients experienced inadequate pain management (PMI < 0). Specifically, patients with KPS ⩾ 90 had a notably lower rate of adequate analgesic therapy (59.3%) compared with those with a KPS < 90 (85.0%). Among outpatients, 23.7% reported inadequate pain management, contrasted with a significantly lower inadequacy rate (3.8%) in palliative care or hospice settings. In addition, in outpatients, pain management adequacy varied with the primary tumor type, showing improved outcomes for patients with lung cancer (89.2%) versus other primary tumors (79.1%). Moreover, in non-outpatients, pain management was less effective for patients receiving radiotherapy on pelvic BMs (89.5%) compared with other sites (95.7%).
Although overall rates of inadequate pain management were lower than seen in previous studies, significant variability exists based on patient health status, care setting, primary tumor type, and site of BMs. These results underscore the need for personalized pain management approaches and highlight specific areas for improvement in outpatient settings and among patients with generally good health but significant pain from BMs.
骨转移(BMs)是癌症患者常见的并发症,常导致严重疼痛,对生活质量产生不利影响,因此需要有效的疼痛管理策略。本研究旨在评估接受姑息性放疗的骨转移患者疼痛管理的有效性,并确定疼痛管理充分性的决定因素。
我们对来自欧洲多个中心的姑息性放疗与炎症研究(PRAIS)试验中的560名患者进行了观察性分析,重点关注用于评估疼痛管理充分性的疼痛管理指数(PMI)。检查的关键预测因素包括卡诺夫斯基功能状态(KPS)、治疗环境、原发肿瘤类型和骨转移部位。
我们的研究结果表明,19.0%的患者疼痛管理不充分(PMI<0)。具体而言,KPS⩾90的患者充分镇痛治疗率(59.3%)明显低于KPS<90的患者(85.0%)。在门诊患者中,23.7%报告疼痛管理不充分,而在姑息治疗或临终关怀环境中,不充分率显著较低(3.8%)。此外,在门诊患者中,疼痛管理的充分性因原发肿瘤类型而异,肺癌患者(89.2%)的结果优于其他原发肿瘤患者(79.1%)。此外,在非门诊患者中,接受盆腔骨转移放疗的患者(89.5%)的疼痛管理效果低于其他部位(95.7%)。
尽管疼痛管理不充分的总体发生率低于以往研究,但基于患者健康状况、护理环境、原发肿瘤类型和骨转移部位存在显著差异。这些结果强调了个性化疼痛管理方法的必要性,并突出了门诊环境以及健康状况总体良好但因骨转移而疼痛严重的患者中需要改进的特定领域。